JPS5835120A - 血液循環改善剤 - Google Patents
血液循環改善剤Info
- Publication number
- JPS5835120A JPS5835120A JP56134985A JP13498581A JPS5835120A JP S5835120 A JPS5835120 A JP S5835120A JP 56134985 A JP56134985 A JP 56134985A JP 13498581 A JP13498581 A JP 13498581A JP S5835120 A JPS5835120 A JP S5835120A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- collagen
- solubilized collagen
- injection
- circulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000017531 blood circulation Effects 0.000 title claims abstract description 11
- 102000008186 Collagen Human genes 0.000 claims abstract description 30
- 108010035532 Collagen Proteins 0.000 claims abstract description 30
- 229920001436 collagen Polymers 0.000 claims abstract description 30
- 230000004087 circulation Effects 0.000 claims abstract description 13
- 239000012528 membrane Substances 0.000 claims abstract description 13
- 239000007924 injection Substances 0.000 claims abstract description 9
- 238000002347 injection Methods 0.000 claims abstract description 9
- 210000000601 blood cell Anatomy 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 206010018910 Haemolysis Diseases 0.000 abstract description 13
- 230000008588 hemolysis Effects 0.000 abstract description 13
- 210000003743 erythrocyte Anatomy 0.000 abstract description 12
- 210000004204 blood vessel Anatomy 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000004089 microcirculation Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 210000001772 blood platelet Anatomy 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 abstract description 3
- 238000005345 coagulation Methods 0.000 abstract description 3
- 230000015271 coagulation Effects 0.000 abstract description 3
- 210000000265 leukocyte Anatomy 0.000 abstract description 3
- 206010003178 Arterial thrombosis Diseases 0.000 abstract description 2
- 206010047249 Venous thrombosis Diseases 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 210000000988 bone and bone Anatomy 0.000 abstract description 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 2
- 210000005259 peripheral blood Anatomy 0.000 abstract description 2
- 239000011886 peripheral blood Substances 0.000 abstract description 2
- 230000002093 peripheral effect Effects 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 230000003381 solubilizing effect Effects 0.000 abstract description 2
- 230000001413 cellular effect Effects 0.000 abstract 2
- 239000000470 constituent Substances 0.000 abstract 2
- 230000004520 agglutination Effects 0.000 abstract 1
- 239000000823 artificial membrane Substances 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 230000001050 lubricating effect Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000035322 succinylation Effects 0.000 description 3
- 238000010613 succinylation reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56134985A JPS5835120A (ja) | 1981-08-28 | 1981-08-28 | 血液循環改善剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56134985A JPS5835120A (ja) | 1981-08-28 | 1981-08-28 | 血液循環改善剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5835120A true JPS5835120A (ja) | 1983-03-01 |
| JPS619288B2 JPS619288B2 (cg-RX-API-DMAC7.html) | 1986-03-22 |
Family
ID=15141223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56134985A Granted JPS5835120A (ja) | 1981-08-28 | 1981-08-28 | 血液循環改善剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5835120A (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6480496A (en) * | 1987-09-22 | 1989-03-27 | Aqua Renaissance Gijutsu | Solubilization of suspended organic matter |
| KR20000055096A (ko) * | 1999-02-03 | 2000-09-05 | 권호철 | 생우피를 유효 성분으로 하는 심장병치료제의 제조방법 |
| JP2002371011A (ja) * | 2001-06-13 | 2002-12-26 | T Hasegawa Co Ltd | 血液流動性改善剤 |
-
1981
- 1981-08-28 JP JP56134985A patent/JPS5835120A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6480496A (en) * | 1987-09-22 | 1989-03-27 | Aqua Renaissance Gijutsu | Solubilization of suspended organic matter |
| KR20000055096A (ko) * | 1999-02-03 | 2000-09-05 | 권호철 | 생우피를 유효 성분으로 하는 심장병치료제의 제조방법 |
| JP2002371011A (ja) * | 2001-06-13 | 2002-12-26 | T Hasegawa Co Ltd | 血液流動性改善剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS619288B2 (cg-RX-API-DMAC7.html) | 1986-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL194909C (nl) | Werkwijze voor de bereiding van gepolymeriseerd hemoglobine en celvrij vervangingsmiddel voor rode bloedlichaampjes op basis daarvan. | |
| Rehm et al. | Changes in blood volume and hematocrit during acute preoperative volume loading with 5% albumin or 6% hetastarch solutions in patients before radical hysterectomy | |
| US4529719A (en) | Modified crosslinked stroma-free tetrameric hemoglobin | |
| US6133425A (en) | Acellular red blood cell substitute | |
| CA2134759A1 (en) | Preparation and method for production of platelet concentrates with significantly prolonged viability during storage | |
| US9511053B2 (en) | Nitric oxide scavengers | |
| Faithfull | Fluorocarbons: Current status and future applications | |
| US4439424A (en) | Synthetic whole blood | |
| Cheung et al. | Cardiopulmonary effects of cuprophane–activated plasma in the swine | |
| Parkins et al. | Gelatin as a plasma substitute: with particular reference to experimental hemorrhage and burn shock | |
| US20030026855A1 (en) | Artificial blood fluids and microflow drag reducing factors for enhanced blood circulation | |
| JP6389125B2 (ja) | 赤血球の処理法 | |
| JP2000507947A (ja) | 無細胞性赤血球代用物を製造する方法及び装置 | |
| Martini et al. | Survival time in severe hemorrhagic shock after perioperative hemodilution is longer with PEG-conjugated human serum albumin than with HES 130/0.4: a microvascular perspective | |
| JPS5835120A (ja) | 血液循環改善剤 | |
| JPS58502204A (ja) | 合成全血およびその製造方法 | |
| US2460550A (en) | Modified globin and method for its preparation | |
| CA1188222A (en) | Agents for improvement of peripheral blood flow | |
| US20120046231A1 (en) | Composition and process for synthesizing polymerized human serum albumin for applications in transfusion medicine | |
| DE69130483T2 (de) | Verbesserter blutersatz | |
| EP0035038B1 (en) | Peripheral circulation failure-curing agent | |
| JPH11116490A (ja) | 血球用洗浄液 | |
| Lang et al. | Stroma-free hemoglobin solutions prepared by crystallization and ultrafiltration methods; comparison of composition and coronary vasoconstrictor potency | |
| RU2704464C1 (ru) | Способ коррекции кровопотери при оперативном разрешении беременных с врастанием плаценты | |
| RU1801499C (ru) | Способ лечени гипоксических состо ний |